Fate Therapeutics

Fate Therapeutics EBIT

The EBIT of Fate Therapeutics (FATE) as of Oct 24, 2026 is -147.70 M USD. In the previous year, EBIT was -210.28 M USD — a change of -29.76% (higher).

EBIT

-147.70 MUSD

YoY

-29.76%

Last updated:

In 2025, Fate Therapeutics's EBIT was -147.70 M USD, a -29.76% increase from the -210.28 M USD EBIT recorded in the previous year.

The Fate Therapeutics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-190.51 M USD
Jan 1, 2024
-210.28 M USD
Jan 1, 2025
-147.70 M USD
Jan 1, 2026 (e)
-124.77 M USD
Jan 1, 2027 (e)
-145.04 M USD
Jan 1, 2028 (e)
-159.87 M USD
Jan 1, 2029 (e)
-126.39 M USD
Jan 1, 2030 (e)
-96.70 M USD
The Fate Therapeutics EBIT history
YEAREBITYoY
est-96.70 MUSD-23.50%
est-126.39 MUSD-20.94%
est-159.87 MUSD+10.22%
est-145.04 MUSD+16.25%
est-124.77 MUSD-15.53%
-147.70 MUSD-29.76%
-210.28 MUSD+10.37%
-190.51 MUSD-38.22%
-308.39 MUSD+42.12%
-216.99 MUSD+69.41%
-128.09 MUSD+27.16%
-100.73 MUSD+50.13%
-67.09 MUSD+58.82%
-42.24 MUSD+32.16%
-31.96 MUSD+15.05%
-27.78 MUSD+11.56%
-24.90 MUSD+40.90%
-17.68 MUSD+30.38%
-13.56 MUSD+1.99%
-13.29 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fate Therapeutics Revenue

Fate Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
63.53 M USD
-190.51 M USD
-160.93 M USD
Jan 1, 2024
13.63 M USD
-210.28 M USD
-186.26 M USD
Jan 1, 2025
6.65 M USD
-147.70 M USD
-136.32 M USD
Jan 1, 2026 (e)
5.61 M USD
-124.77 M USD
-126.87 M USD
Jan 1, 2027 (e)
4.63 M USD
-145.04 M USD
-124.86 M USD
Jan 1, 2028 (e)
4.86 M USD
-159.87 M USD
-130.16 M USD
Jan 1, 2029 (e)
26.38 M USD
-126.39 M USD
-126.39 M USD
Jan 1, 2030 (e)
106.54 M USD
-96.70 M USD
-96.70 M USD

Fate Therapeutics Margins

Fate Therapeutics stock margins

The Fate Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fate Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fate Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
-147.41 %
-299.86 %
-253.30 %
Jan 1, 2024
-769.57 %
-1,542.63 %
-1,366.46 %
Jan 1, 2025
-94.12 %
-2,222.45 %
-2,051.08 %
Jan 1, 2026 (e)
-94.12 %
-2,225.90 %
-2,263.36 %
Jan 1, 2027 (e)
-94.12 %
-3,130.79 %
-2,695.16 %
Jan 1, 2028 (e)
-94.12 %
-3,286.54 %
-2,675.91 %
Jan 1, 2029 (e)
-94.12 %
-479.06 %
-479.06 %
Jan 1, 2030 (e)
-94.12 %
-90.76 %
-90.76 %

Fate Therapeutics Stock analysis

What does Fate Therapeutics do? Fate Therapeutics Inc is a biotechnology company specializing in the development of cell therapies. The company was founded in 2007 by four scientists who recognized the need for new therapies and treatment options. Their goal was to find new ways to promote tissue and organ regeneration and repair by harnessing the biological mechanisms within cells. Fate Therapeutics' business model is to develop and market state-of-the-art cell therapies based on human stem cells. These stem cells are typically obtained from patients' bone marrow or adipose tissue and then cultured in specialized cell cultures to prepare them for medical use. Fate Therapeutics currently offers several different products and services, including: - Cell therapies for the treatment of cancer: The company has developed a range of cell therapies aimed at boosting the immune system and mobilizing against cancer cells. These therapies are based on the method of extracting so-called T cells from the patient's blood, growing and modifying them in the lab to enhance their ability to target cancer cells. - Therapies for the treatment of genetic diseases: Fate Therapeutics has also developed cell therapies aimed at treating genetic mutations or defects. These therapies are based on the method of obtaining pluripotent stem cells (iPS cells) from the patient's blood or adipose tissue and then differentiating them into specialized cell types that can be used to repair tissue damage or correct genetic defects. - Services to support research and development: Fate Therapeutics also offers services to assist researchers in developing and testing their own cell therapies. This includes the cell cultures, devices, and assays needed to generate and analyze new cell lines. Fate Therapeutics is divided into several divisions to better manage its various business areas. These divisions include: - Research & Development: This division is responsible for conducting basic research to develop and test new cell therapies. This includes both foundational research and the clinical trials necessary to evaluate the effectiveness and safety of new therapies. - Manufacturing: This division is responsible for the large-scale production and processing of Fate Therapeutics' cell therapies. The company has multiple production facilities in the United States and internationally to ensure swift and efficient manufacturing and delivery of its therapies. - Sales & Marketing: This division is responsible for marketing and selling Fate Therapeutics' cell therapies. The company works closely with doctors, clinics, and medical facilities to ensure that therapies reach the patients who need them. Overall, Fate Therapeutics has become a global leader in the development of cell therapies. The company has made significant progress in recent years in developing new therapies and continues to work on finding innovative solutions to medical challenges. With its competent leadership and top-notch products and services, Fate Therapeutics Inc. is poised for even greater success in the future. Fate Therapeutics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Fate Therapeutics's EBIT

Fate Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Fate Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Fate Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Fate Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Fate Therapeutics stock

EBIT of Fate Therapeutics is -147.70 M USD in 2025.

EBIT of Fate Therapeutics changed from -210.28 M USD to -147.70 M USD, representing a -29.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Fate Therapeutics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Fate Therapeutics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fate Therapeutics

All Key Metrics — Fate Therapeutics